Cycloheximide chase assays are an experimental technique used in molecular and cellular biology to measure steady state protein stability. Cycloheximide is a drug that inhibits the elongation step in eukaryotic protein translation, thereby preventing protein synthesis.[1] The addition of cycloheximide to cultured cells followed by protein lysis at multiple timepoints is conducted to observe protein degradation over time and can be used to determine a protein's half-life. These assays are often followed by western blotting to assess protein abundance and can be analyzed using quantitative tools such as ImageJ.[2]
Implementation
Cycloheximide chase assays have been conducted using a variety of cell types such as yeast and mammalian cell lines.[3][4][5][6] Depending on the cell system used for analysis, the assay may vary in application and time course. For example, yeast cells expressing a protein substrate of interest typically require cycloheximide chases lasting up to 90 minutes to allow protein turnover to occur.[4][7] In contrast, proteins that are expressed in mammalian cell lines tend to me more stable at steady state and may require a chase lasting 3 to 8 hours.[4][5][6] Depending on the complexity of the protein and whether it is overexpressed or endogenous to the model system, the required length of the chase may vary. To ensure that protein synthesis is inhibited during the entire chase, cycloheximide is often spiked into the sample every few hours.
In yeast, deletion strains are frequently used to assess protein stability over time with cycloheximide chases. For example, yeast strains lacking critical degradation machinery such as chaperones, E3 ligases, and vacuolar proteins are often used to determine the mechanism of degradation for a protein substrate of interest.[5][7] Drug treatments (such as MG132) are also used to inhibit steps of degradation, followed by a cycloheximide chase to observe how the stability of a protein of interest is affected.[3][4][7] These experiments may be conducted in mammalian cells with the implementation of compatible knockdown procedures in place of the yeast deletion strains.[4]
Cycloheximide chases are also valuable for assessing how different mutations affect the stability of a protein. Experiments have been conducted in yeast and mammalian cells to determine the critical residues required for protein stability and how disease-associated mutations may be affecting protein half-lives within the cell.[3][6] This information is valuable for understanding the complexities of protein folding and how mutations contribute to the pathogenesis of the diseases they are associated with.
Advantages
There are many benefits to using cycloheximide chase assays as opposed to other methods that assess protein stability. Cycloheximide chases can be used with a wide variety of model systems and can be implemented to study almost any protein substrate. Cycloheximide is relatively inexpensive compound compared to other drugs and it is effective when used in low doses for short periods of time. Pulse chase assays are an alternative method to cycloheximide chase assays and involve the radioactive labeling of newly translated proteins followed by a similar “chase” period.[8] While this method is informative and provides the benefit of observing nascent protein abundance, the radioactive material it requires is expensive with a shorter shelf-life and demands more caution to use than cycloheximide.
Disadvantages
Some disadvantages to conducting cycloheximide chase assays include the toxic nature of cycloheximide. When used at high concentrations over a long period of time, cycloheximide will damage the DNA within the cell and impair critical cellular function.[9] For this reason, cycloheximide chases do not typically last for more than 12 hours. This presents a limitation if the turnover of a particularly stable protein is being studied. Additionally, cycloheximide chases only offer the ability to look at steady state proteins levels as opposed to newly translated protein levels such as with pulse chase. Therefore, only protein degradation and not protein maturation is able to be observed.
References
edit- ^ Schneider-Poetsch, Tilman; Ju, Jianhua; Eyler, Daniel E.; Dang, Yongjun; Bhat, Shridhar; Merrick, William C.; Green, Rachel; Shen, Ben; Liu, Jun O. (2010). "Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin". Nature Chemical Biology. 6 (3): 209–217. doi:10.1038/nchembio.304. PMC 2831214. PMID 20118940.
- ^ Girish, V.; Vijayalakshmi, A. (2004). "Affordable image analysis using NIH Image/ImageJ". Indian Journal of Cancer. 41 (1): 47. doi:10.4103/0019-509X.12345. PMID 15105580. S2CID 44965098.
- ^ a b c Preston, G. M.; Guerriero, C. J.; Metzger, M. B.; Michaelis, S.; Brodsky, J. L. (2018). "Substrate Insolubility Dictates Hsp104-Dependent Endoplasmic-Reticulum-Associated Degradation". Molecular Cell. 70 (2): 242–253.e6. doi:10.1016/j.molcel.2018.03.016. PMC 5912696. PMID 29677492.
- ^ a b c d e Kim Chiaw, P.; Hantouche, C.; Wong MJH; Matthes, E.; Robert, R.; Hanrahan, J. W.; Shrier, A.; Young, J. C. (2019). "Hsp70 and DNAJA2 limit CFTR levels through degradation". PLOS ONE. 14 (8): e0220984. Bibcode:2019PLoSO..1420984K. doi:10.1371/journal.pone.0220984. PMC 6692068. PMID 31408507.
- ^ a b c Needham, P. G.; Goeckeler-Fried, J. L.; Zhang, C.; Sun, Z.; Wetzel, A. R.; Bertrand, C. A.; Brodsky, J. L. (2021). "SLC26A9 is selected for endoplasmic reticulum associated degradation (ERAD) via Hsp70-dependent targeting of the soluble STAS domain". The Biochemical Journal. 478 (24): 4203–4220. doi:10.1042/BCJ20210644. PMC 8826537. PMID 34821356.
- ^ a b c Amico, G.; Brandas, C.; Moran, O.; Baroni, D. (2019). "Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors". International Journal of Molecular Sciences. 20 (21): 5463. doi:10.3390/ijms20215463. PMC 6862496. PMID 31683989.
- ^ a b c Needham, P. G.; Mikoluk, K.; Dhakarwal, P.; Khadem, S.; Snyder, A. C.; Subramanya, A. R.; Brodsky, J. L. (2011). "The thiazide-sensitive NaCl cotransporter is targeted for chaperone-dependent endoplasmic reticulum-associated degradation". The Journal of Biological Chemistry. 286 (51): 43611–43621. doi:10.1074/jbc.M111.288928. PMC 3243568. PMID 22027832.
- ^ Sun, Z.; Guerriero, C. J.; Brodsky, J. L. (2021). "Substrate ubiquitination retains misfolded membrane proteins in the endoplasmic reticulum for degradation". Cell Reports. 36 (12): 109717. doi:10.1016/j.celrep.2021.109717. PMC 8503845. PMID 34551305.
- ^ Bašić-Zaninović, Tamara; Papeš, Dražena; Franekić, Jasna (1991). "Cycloheximide genotoxicity in in vitro and in vivo test systems". Mutation Research Letters. 263 (4): 203–210. doi:10.1016/0165-7992(91)95002-L. PMID 1861684.